Assignee
PDS BIOTECHNOLOGY CORP
US·12 granted patents·15 pending applications·150 citations·filing 2005–2024
Top patents by PatentIndex Score
27 records- 0194US11801257B2Stimulation of an immune response by enantiomers of cationic lipidsPDS BIOTECHNOLOGY CORP·Filed 2020·Granted Oct 31, 2023·4 cites·13 claims
- 0294US10828364B2Method for reducing a myeloid derived suppressor cell population with cationic lipid vaccine compositionsPDS BIOTECHNOLOGY CORP·Filed 2019·Granted Nov 10, 2020·8 cites·19 claims
- 0392US11911465B2Vaccine compositions and methods of usePDS BIOTECHNOLOGY CORP·Filed 2021·Granted Feb 27, 2024·2 cites·12 claims
- 0492US10702541B2Stimulation of an immune response by enantiomers of cationic lipidsPDS BIOTECHNOLOGY CORP·Filed 2017·Granted Jul 7, 2020·7 cites·13 claims
- 0591US12201685B2Methods of modulating immune responses with cationic lipid vaccine compositionsPDS BIOTECHNOLOGY CORP·Filed 2020·Granted Jan 21, 2025·2 cites·18 claims
- 0691US11401306B2HPV16 non HLA-restricted t-cell vaccines, compositions and methods of use thereofPDS BIOTECHNOLOGY CORP·Filed 2017·Granted Aug 2, 2022·9 cites·10 claims
- 0791US7303881B2Antigen delivery compositions and methods of usePDS BIOTECHNOLOGY CORP·Filed 2005·Granted Dec 4, 2007·97 cites·5 claims
- 0888US10286064B2Cationic lipid vaccine compositions and methods of usePDS BIOTECHNOLOGY CORP·Filed 2013·Granted May 14, 2019·9 cites·3 claims
- 0987US11904015B2Vaccine compositions and methods of usePDS BIOTECHNOLOGY CORP·Filed 2019·Granted Feb 20, 2024·2 cites·18 claims
- 1087US11638753B2Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapyPDS BIOTECHNOLOGY CORP·Filed 2019·Granted May 2, 2023·4 cites·18 claims
- 1186US11612652B2Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapyPDS BIOTECHNOLOGY CORP·Filed 2016·Granted Mar 28, 2023·4 cites·6 claims
- 1283US11911359B2Stimulation of an immune response by cationic lipidsPDS BIOTECHNOLOGY CORP·Filed 2014·Granted Feb 27, 2024·2 cites·21 claims
- 1377US2025018029A1Methods to alter the tumor microenvironment for effective cancer immunotherapyPDS BIOTECHNOLOGY CORP·Filed 2024·Application pending·0 cites
- 1472US2023285551A1Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapyPDS BIOTECHNOLOGY CORP·Filed 2023·Application pending·0 cites
- 1572US2021346496A1Cationic lipid vaccine compositions and methods of usePDS BIOTECHNOLOGY CORP·Filed 2021·Application pending·0 cites
- 1671US2021346333A1Stimulation of an immune response by cationic lipidsPDS BIOTECHNOLOGY CORP·Filed 2021·Application pending·0 cites
- 1771US2022031650A1Stimulation of an immune response by cationic lipidsPDS BIOTECHNOLOGY CORP·Filed 2021·Application pending·0 cites
- 1869US2023052399A1Methods to alter the tumor microenvironment for effective cancer immunotherapyPDS BIOTECHNOLOGY CORP·Filed 2022·Application pending·0 cites
- 1969US2021308157A1Stimulation of an immune response by enantiomers of cationic lipidsPDS BIOTECHNOLOGY CORP·Filed 2021·Application pending·0 cites
- 2067US2022332768A1Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereofPDS BIOTECHNOLOGY CORP·Filed 2022·Application pending·0 cites
- 2165US2024316178A1Recombinant protein vaccines formulated with enantio-specific cationic lipid r-dotap and methods of use thereofPDS BIOTECHNOLOGY CORP·Filed 2023·Application pending·0 cites
- 2265US2024317828A1T cell activating immunotherapeutic for treatment of mucin 1 protein expressing human cancersPDS BIOTECHNOLOGY CORP·Filed 2023·Application pending·0 cites
- 2365US2024317833A1Non-hla restricted t cell vaccine for tcr gamma alternate reading frame protein (tarp) protein expressing cancersPDS BIOTECHNOLOGY CORP·Filed 2023·Application pending·0 cites
- 2453US2022160867A1Methods and compositions comprising cationic lipids for immunotherapy by direct tumor injectionPDS BIOTECHNOLOGY CORP·Filed 2021·Application pending·0 cites
- 2551US2019275145A1Particulate vaccine formulationsPDS BIOTECHNOLOGY CORP·Filed 2019·Application pending·0 cites
- 2649US2018221475A1Methods to alter the tumor microenvironment for effective cancer immunotherapyPDS BIOTECHNOLOGY CORP·Filed 2017·Application pending·0 cites
- 2729US2008131455A1Antigen Delivery Compositions And Methods Of UsePDS BIOTECHNOLOGY CORP·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when PDS BIOTECHNOLOGY CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →